Cargando…

Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal

BACKGROUND: Mycobacterium tuberculosis(MTB) remains a major public health problem worldwide, and emergence of drug-resistant TB has become a significant obstacle to effective TB control. However, the rate of MTB and rifampicin resistant-MTB (RR-MTB) in the Nepalese setting has not been studied exten...

Descripción completa

Detalles Bibliográficos
Autores principales: Sah, Shiv Kumar, Bhattarai, Pramod Raj, Shrestha, Anjana, Dhami, Deepak, guruwacharya, Deepa, Shrestha, Renu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445509/
https://www.ncbi.nlm.nih.gov/pubmed/32903905
http://dx.doi.org/10.2147/IDR.S263795
_version_ 1783574003310395392
author Sah, Shiv Kumar
Bhattarai, Pramod Raj
Shrestha, Anjana
Dhami, Deepak
guruwacharya, Deepa
Shrestha, Renu
author_facet Sah, Shiv Kumar
Bhattarai, Pramod Raj
Shrestha, Anjana
Dhami, Deepak
guruwacharya, Deepa
Shrestha, Renu
author_sort Sah, Shiv Kumar
collection PubMed
description BACKGROUND: Mycobacterium tuberculosis(MTB) remains a major public health problem worldwide, and emergence of drug-resistant TB has become a significant obstacle to effective TB control. However, the rate of MTB and rifampicin resistant-MTB (RR-MTB) in the Nepalese setting has not been studied extensively. Therefore, the present study aims to assess the rate of MTB and RR-MTB and further determine the factors associated with it. METHODS: A retrospective cross-sectional study, among national representative data of 990 consecutive presumptive TB resister of patients subjected to the GeneXpert test that presented to the tuberculosis referral hospital, was conducted over a one year period from February 2018 to January 2019. Significance for the difference for categorical data was performed by Chi-square test and factors associated with MTB and RR-MTB were assessed using binary logistic regression yielding OR with 95%CI. RESULTS: Of total 990 presumptive tuberculosis analyzed cases, median ages of the patients were 39±19.09 years and two-thirds of the patients were male 653 (66.0%). The estimated prevalence of MTB in presumptive TB patients was 13.8% (95%CI: 11.88%–16.16%), and risk for MTB was significantly associated with previously treated patients: OR: 10.4 (P<0.001). The estimated prevalence of RR-MTB in MTB confirmed patients was 10.2% (4.97%–15.1%). Our study confirmed no association of RR-TB with age, sex, ethnicity, geographical diversity and previous history of treatment failure (P>0.05). CONCLUSION: The overall prevalence of MTB and RR-MTB was high in Nepalese study population,  and that being previously treated with anti-TB drug remained significant predictors for MTB; proactive measures are urgently needed to address the challenge of prompt diagnosis, early management and improved monitoring of treatment to limit the emergence drug-resistant MTB strains in the community.
format Online
Article
Text
id pubmed-7445509
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74455092020-09-04 Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal Sah, Shiv Kumar Bhattarai, Pramod Raj Shrestha, Anjana Dhami, Deepak guruwacharya, Deepa Shrestha, Renu Infect Drug Resist Original Research BACKGROUND: Mycobacterium tuberculosis(MTB) remains a major public health problem worldwide, and emergence of drug-resistant TB has become a significant obstacle to effective TB control. However, the rate of MTB and rifampicin resistant-MTB (RR-MTB) in the Nepalese setting has not been studied extensively. Therefore, the present study aims to assess the rate of MTB and RR-MTB and further determine the factors associated with it. METHODS: A retrospective cross-sectional study, among national representative data of 990 consecutive presumptive TB resister of patients subjected to the GeneXpert test that presented to the tuberculosis referral hospital, was conducted over a one year period from February 2018 to January 2019. Significance for the difference for categorical data was performed by Chi-square test and factors associated with MTB and RR-MTB were assessed using binary logistic regression yielding OR with 95%CI. RESULTS: Of total 990 presumptive tuberculosis analyzed cases, median ages of the patients were 39±19.09 years and two-thirds of the patients were male 653 (66.0%). The estimated prevalence of MTB in presumptive TB patients was 13.8% (95%CI: 11.88%–16.16%), and risk for MTB was significantly associated with previously treated patients: OR: 10.4 (P<0.001). The estimated prevalence of RR-MTB in MTB confirmed patients was 10.2% (4.97%–15.1%). Our study confirmed no association of RR-TB with age, sex, ethnicity, geographical diversity and previous history of treatment failure (P>0.05). CONCLUSION: The overall prevalence of MTB and RR-MTB was high in Nepalese study population,  and that being previously treated with anti-TB drug remained significant predictors for MTB; proactive measures are urgently needed to address the challenge of prompt diagnosis, early management and improved monitoring of treatment to limit the emergence drug-resistant MTB strains in the community. Dove 2020-08-20 /pmc/articles/PMC7445509/ /pubmed/32903905 http://dx.doi.org/10.2147/IDR.S263795 Text en © 2020 Sah et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sah, Shiv Kumar
Bhattarai, Pramod Raj
Shrestha, Anjana
Dhami, Deepak
guruwacharya, Deepa
Shrestha, Renu
Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal
title Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal
title_full Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal
title_fullStr Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal
title_full_unstemmed Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal
title_short Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal
title_sort rifampicin-resistant mycobacterium tuberculosis by genexpert mtb/rif and associated factors among presumptive pulmonary tuberculosis patients in nepal
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7445509/
https://www.ncbi.nlm.nih.gov/pubmed/32903905
http://dx.doi.org/10.2147/IDR.S263795
work_keys_str_mv AT sahshivkumar rifampicinresistantmycobacteriumtuberculosisbygenexpertmtbrifandassociatedfactorsamongpresumptivepulmonarytuberculosispatientsinnepal
AT bhattaraipramodraj rifampicinresistantmycobacteriumtuberculosisbygenexpertmtbrifandassociatedfactorsamongpresumptivepulmonarytuberculosispatientsinnepal
AT shresthaanjana rifampicinresistantmycobacteriumtuberculosisbygenexpertmtbrifandassociatedfactorsamongpresumptivepulmonarytuberculosispatientsinnepal
AT dhamideepak rifampicinresistantmycobacteriumtuberculosisbygenexpertmtbrifandassociatedfactorsamongpresumptivepulmonarytuberculosispatientsinnepal
AT guruwacharyadeepa rifampicinresistantmycobacteriumtuberculosisbygenexpertmtbrifandassociatedfactorsamongpresumptivepulmonarytuberculosispatientsinnepal
AT shrestharenu rifampicinresistantmycobacteriumtuberculosisbygenexpertmtbrifandassociatedfactorsamongpresumptivepulmonarytuberculosispatientsinnepal